Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Rien van Marwijk Kooy"'
Autor:
Dietger Niederwieser, Dirk Hasenclever, Wolfgang Berdel, Bart J. Biemond, Haifa Al-Ali, Yves Chalandon, Michel van Gelder, Christian Junghanß, Gösta Gahrton, Mathias Hänel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jacob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Leo F. Verdonck, Vladan Vucinic, Bob Löwenberg, Jan Cornelissen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged
Externí odkaz:
https://doaj.org/article/e24e854d3915489f8bfdf3f02374efc6
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Dietger Niederwieser, Dirk Hasenclever, Wolfgang E. Berdel, Bart J. Biemond, Haifa Kathrin Al-Ali, Yves Chalandon, Michel Van Gelder, Christian Junghanss, Goesta Gahrton, Mathias Haenel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen J.W.M. Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jakob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Peter JM Valk, Bob Lowenberg, Jan J. Cornelissen
Publikováno v:
Blood. 140:2126-2129
Autor:
Rien van Marwijk Kooy, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Wim Terpstra, Dana A. Chitu, Okke de Weerdt, Dimitri Breems, Bob Löwenberg, Jürgen Kuball, Marie-Christiane Vekemans, Edo Vellenga, Dries Deeren, Bart J. Biemond, Gerwin Huls, Saskia K. Klein, Harm Sinnige, Violaine Havelange, Mojca Jongen-Lavrencic, Beata Hodossy, Carlos Graux
Publikováno v:
Blood, 133, 13, pp. 1457-1464
Blood, Vol. 133, no. 13, p. 1457-1464 (2019)
Huls, G, Chitu, D A, Havelange, V, Jongen-Lavrencic, M, van de Loosdrecht, A A, Biemond, B J, Sinnige, H, Hodossy, B, Graux, C, Kooy, R V M, de Weerdt, O, Breems, D, Klein, S, Kuball, J R, Deeren, D, Terpstra, W, Vekemans, M-C, Ossenkoppele, G J, Vellenga, E, Löwenberg, B & Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) 2019, ' Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients ', Blood, vol. 133, no. 13, pp. 1457-1464 . https://doi.org/10.1182/blood-2018-10-879866
Blood, 133(13), 1457-1464. American Society of Hematology
Blood, 133, 1457-1464
Blood, 133(13), 1457-1464. AMER SOC HEMATOLOGY
Blood, 133(13), 1457. American Society of Hematology
Blood, Vol. 133, no. 13, p. 1457-1464 (2019)
Huls, G, Chitu, D A, Havelange, V, Jongen-Lavrencic, M, van de Loosdrecht, A A, Biemond, B J, Sinnige, H, Hodossy, B, Graux, C, Kooy, R V M, de Weerdt, O, Breems, D, Klein, S, Kuball, J R, Deeren, D, Terpstra, W, Vekemans, M-C, Ossenkoppele, G J, Vellenga, E, Löwenberg, B & Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) 2019, ' Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients ', Blood, vol. 133, no. 13, pp. 1457-1464 . https://doi.org/10.1182/blood-2018-10-879866
Blood, 133(13), 1457-1464. American Society of Hematology
Blood, 133, 1457-1464
Blood, 133(13), 1457-1464. AMER SOC HEMATOLOGY
Blood, 133(13), 1457. American Society of Hematology
The prevention of relapse is the major therapeutic challenge in older patients with acute myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive chemotherapy. In this randomized phase 3 study (HOVON97) in older patients (≥6
Autor:
Peter J. M. Valk, Yves Chalandon, Thomas Pabst, Markus G. Manz, Dimitri Breems, Maaike Sohne, Bob Löwenberg, Emanuele Ammatuna, Marjolein van der Poel, Sabine Blum, Dries Deeren, Rien van Marwijk Kooy, Dana A. Chitu, Mojca Jongen-Lavrencic, Lidwine W. Tick, Marie Cecile J.C. Legdeur, Gerwin Huls, Saskia K. Klein, Danielle van Lammeren-Venema, Gert J. Ossenkoppele, Georg Stussi, Arjan A. van de Loosdrecht, Isabelle A van Zeventer, Rinske S. Boersma, M. Fehr, Mels Hoogendoorn, Jacqueline Cloos, Laimonas Griskevicius
Publikováno v:
Blood advances, vol. 4, no. 18, pp. 4267-4277
Blood Advances, Vol. 4, No 18 (2020) pp. 4267-4277
Blood, 4(18), 4267-4277. AMER SOC HEMATOLOGY
Blood, 4(18), 4267-4277. American Society of Hematology
Blood advances, 4(18), 4267-4277. American Society of Hematology
Huls, G, Chitu, D A, Pabst, T, Klein, S K, Stussi, G, Griskevicius, L, Valk, P J M, Cloos, J, van de Loosdrecht, A A, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, M G, Söhne, M, Kooy, R V M, Deeren, D, van der Poel, M W M, Legdeur, M C, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Löwenberg, B & Ossenkoppele, G J 2020, ' Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS ', Blood, vol. 4, no. 18, pp. 4267-4277 . https://doi.org/10.1182/BLOODADVANCES.2020002846
Blood advances, 4(18), 4267-4277. The American Society of Hematology
Blood Adv
Blood Advances, Vol. 4, No 18 (2020) pp. 4267-4277
Blood, 4(18), 4267-4277. AMER SOC HEMATOLOGY
Blood, 4(18), 4267-4277. American Society of Hematology
Blood advances, 4(18), 4267-4277. American Society of Hematology
Huls, G, Chitu, D A, Pabst, T, Klein, S K, Stussi, G, Griskevicius, L, Valk, P J M, Cloos, J, van de Loosdrecht, A A, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, M G, Söhne, M, Kooy, R V M, Deeren, D, van der Poel, M W M, Legdeur, M C, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Löwenberg, B & Ossenkoppele, G J 2020, ' Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS ', Blood, vol. 4, no. 18, pp. 4267-4277 . https://doi.org/10.1182/BLOODADVANCES.2020002846
Blood advances, 4(18), 4267-4277. The American Society of Hematology
Blood Adv
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f035f8641df261cae7346abf960dbaaf
https://serval.unil.ch/notice/serval:BIB_BA95A00DDE07
https://serval.unil.ch/notice/serval:BIB_BA95A00DDE07
Autor:
Lotte E, van der Wagen, Alberto, Miranda-Bedate, Anke, Janssen, Febilla, Fernando, Nagesha, Appukudige, Sanne, van Dooremalen, Kasper, Westinga, Rick, Admiraal, Magdalena J, Lorenowicz, Gerwin, Huls, Jeroen J W M, Janssen, Annoek E C, Broers, Walter J F M, van der Velden, Rien, van Marwijk Kooy, Mette D, Hazenberg, Colin, de Haar, Caroline, Lindemans, Jaap, Jan Boelens, Jürgen, Kuball
Publikováno v:
Bone marrow transplantation. 55(11)
Autor:
Colin de Haar, Kasper Westinga, Mette D. Hazenberg, Caroline A. Lindemans, Sanne van Dooremalen, Rick Admiraal, Lotte van der Wagen, Jürgen Kuball, Magdalena J. Lorenowicz, Anke Janssen, Jaap Jan Boelens, Walter J.F.M. van der Velden, Febilla Fernando, Nagesha Appukudige, Rien van Marwijk Kooy, Annoek E.C. Broers, Jeroen Janssen, Gerwin Huls, Alberto Miranda-Bedate
Publikováno v:
Bone Marrow Transplantation, 55, 2188-2192
Bone Marrow Transplantation, 55(11), 2188-2192. Nature Publishing Group
Bone marrow transplantation, 55(11), 2188-2192. Nature Publishing Group
van der Wagen, L E, Miranda-Bedate, A, Janssen, A, Fernando, F, Appukudige, N, van Dooremalen, S, Westinga, K, Admiraal, R, Lorenowicz, M J, Huls, G, Janssen, J J W M, Broers, A E C, van der Velden, W J F M, van Marwijk Kooy, R, Hazenberg, M D, de Haar, C, Lindemans, C, Jan Boelens, J & Kuball, J 2020, ' Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile ', Bone Marrow Transplantation, vol. 55, no. 11, pp. 2188-2192 . https://doi.org/10.1038/s41409-020-0910-9
Bone Marrow Transplantation, 55, 11, pp. 2188-2192
Bone Marrow Transplantation, 55(11), 2188-2192. Nature Publishing Group
Bone marrow transplantation, 55(11), 2188-2192. Nature Publishing Group
van der Wagen, L E, Miranda-Bedate, A, Janssen, A, Fernando, F, Appukudige, N, van Dooremalen, S, Westinga, K, Admiraal, R, Lorenowicz, M J, Huls, G, Janssen, J J W M, Broers, A E C, van der Velden, W J F M, van Marwijk Kooy, R, Hazenberg, M D, de Haar, C, Lindemans, C, Jan Boelens, J & Kuball, J 2020, ' Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile ', Bone Marrow Transplantation, vol. 55, no. 11, pp. 2188-2192 . https://doi.org/10.1038/s41409-020-0910-9
Bone Marrow Transplantation, 55, 11, pp. 2188-2192
Contains fulltext : 229413.pdf (Publisher’s version ) (Closed access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b48fc123a55f88a9f68c16049df95b
http://hdl.handle.net/2066/229413
http://hdl.handle.net/2066/229413
Autor:
Wendy Deenik, Willem M. Smit, Jeroen Janssen, Noortje Thielen, Gert J. Ossenkoppele, Pieter Sonneveld, Gregor Verhoef, Peter J. M. Valk, J.H. Frederik Falkenburg, Harm Sinnige, Rianne A. H. M. Ammerlaan, Anton Schattenberg, Isabel W. T. Chu, M. Schipperus, Bronno van der Holt, Jan J. Cornelissen, Rien van Marwijk Kooy, Marie José Kersten
Publikováno v:
Annals of Hematology, 92, 8, pp. 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Item does not contain fulltext Despite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease still pose a considerable problem. In this multicenter, ran
Autor:
Mark H.H Kramer, Monique Steijaert, Bob Löwenberg, Pierre W. Wijermans, Rien van Marwijk Kooy, Peter C. Huijgens, Gregor Verhoef, Simon Daenen, Harry C. Schouten, Leo F. Verdonck, Bronno van der Holt, Pieter Sonneveld, Augustin Ferrant, Eva van den Berg
Publikováno v:
Leukemia Research. 28:1057-1067
Cyclosporin A (CsA) inhibits the P-gp pump that can be responsible for failure of cytostatic treatment in acute myeloid leukaemia (AML). Eighty patients with relapsing/refractory AML were randomly assigned to mitoxantrone (M) and etoposide (VP) (MVP)
Autor:
Canan Alhan, Marie-Cecile Legdeur, Petra Muus, Edo Vellenga, Dana A. Chitu, Bea Tanis, Saskia K. Klein, Inge de Greef, Heleen Visser-Wisselaar, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Jurgen Wegman, Annelies Verbrugge, Wendy Deenik, Eline M. P. Cremers, Theresia M. Westers, Mojca Jongen-Lavrencic, Rien van Marwijk-Kooy, Tanja van Maanen, Joop H. Jansen, Pierre W. Wijermans
Publikováno v:
Blood. 128:224-224
Purpose: This randomized phase II study (HOVON89) in patients with low/int-1 risk MDS refractory or unlikely to respond to erythropoietin and granulocyte-colony stimulating factor (EPO/G-CSF) assessed efficacy and safety of lenalidomide without (Arm